Who has invested in ABL Bio?

Eli Lilly and Company are named among the investors backing ABL Bio.

ABL Bio Funding: $55M Raised, Series A

ABL Bio funding overview

ABL Bio is based in Seoul, South Korea. ABL Bio has raised $55M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A. Investors on record include Eli Lilly and Company.

ABL Bio at a glance

Total raised: $55M
Latest round: Series A
Headquarters: Seoul, South Korea
Notable investors: Eli Lilly and Company

Frequently asked about ABL Bio funding

How much has ABL Bio raised?: ABL Bio has raised $55M in total disclosed funding across the rounds on record.
Who has invested in ABL Bio?: Eli Lilly and Company are named among the investors backing ABL Bio.
What was the latest ABL Bio funding round?: The most recent disclosed round is a Series A.
Where is ABL Bio based?: ABL Bio is based in Seoul, South Korea.

ABL Bio totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Seoul below to benchmark round size and investor mix.

ABL Bio Funding: $55M Raised, Series A

ABL Bio funding overview

ABL Bio at a glance

Frequently asked about ABL Bio funding

Companies related to ABL Bio (36)

Browse related funding lists (5)